JP2020533353A - アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用 - Google Patents

アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用 Download PDF

Info

Publication number
JP2020533353A
JP2020533353A JP2020514915A JP2020514915A JP2020533353A JP 2020533353 A JP2020533353 A JP 2020533353A JP 2020514915 A JP2020514915 A JP 2020514915A JP 2020514915 A JP2020514915 A JP 2020514915A JP 2020533353 A JP2020533353 A JP 2020533353A
Authority
JP
Japan
Prior art keywords
subject
canakinumab
gebokizumab
administration
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020514915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533353A5 (enExample
Inventor
ムポフ，シェファード
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020533353A publication Critical patent/JP2020533353A/ja
Publication of JP2020533353A5 publication Critical patent/JP2020533353A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2020514915A 2017-09-13 2018-09-11 アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用 Withdrawn JP2020533353A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762557929P 2017-09-13 2017-09-13
US62/557,929 2017-09-13
US201862647088P 2018-03-23 2018-03-23
US62/647,088 2018-03-23
PCT/IB2018/056928 WO2019053591A1 (en) 2017-09-13 2018-09-11 USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS

Publications (2)

Publication Number Publication Date
JP2020533353A true JP2020533353A (ja) 2020-11-19
JP2020533353A5 JP2020533353A5 (enExample) 2021-10-21

Family

ID=63708416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514915A Withdrawn JP2020533353A (ja) 2017-09-13 2018-09-11 アルコール性肝炎の治療のためのｉｌ−１ｂ結合抗体の使用

Country Status (14)

Country Link
US (3) US20200207848A1 (enExample)
EP (1) EP3717006A1 (enExample)
JP (1) JP2020533353A (enExample)
KR (1) KR20200052331A (enExample)
CN (1) CN111315412A (enExample)
AU (1) AU2018333106A1 (enExample)
BR (1) BR112020004903A2 (enExample)
CA (1) CA3075711A1 (enExample)
CL (1) CL2020000631A1 (enExample)
IL (1) IL273204A (enExample)
MX (1) MX2020002813A (enExample)
RU (1) RU2020113234A (enExample)
TW (1) TW201920269A (enExample)
WO (1) WO2019053591A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013507929A (ja) * 2009-10-15 2013-03-07 アボット・ラボラトリーズ Ｉｌ−１結合蛋白質
JP2015231997A (ja) * 2008-12-10 2015-12-24 ノバルティス アーゲー 抗体製剤
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
WO2015083120A1 (en) * 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
MX2016014731A (es) * 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
KR101695848B1 (ko) * 2015-03-03 2017-01-13 한국과학기술원 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015231997A (ja) * 2008-12-10 2015-12-24 ノバルティス アーゲー 抗体製剤
JP2013507929A (ja) * 2009-10-15 2013-03-07 アボット・ラボラトリーズ Ｉｌ−１結合蛋白質
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DHIMOLEA, E., MABS, vol. 2, no. 1, JPN6022035205, 2010, pages 3 - 13, ISSN: 0004854372 *
PETRASEK, J. ET AL., J CLIN INVEST, vol. 122, no. 10, JPN6022035208, 2012, pages 3476 - 3489, ISSN: 0004854371 *

Also Published As

Publication number Publication date
TW201920269A (zh) 2019-06-01
WO2019053591A1 (en) 2019-03-21
MX2020002813A (es) 2020-07-21
AU2018333106A1 (en) 2020-04-02
US20200207848A1 (en) 2020-07-02
CA3075711A1 (en) 2019-03-21
EP3717006A1 (en) 2020-10-07
IL273204A (en) 2020-04-30
US20230235043A1 (en) 2023-07-27
US20210309736A1 (en) 2021-10-07
RU2020113234A3 (enExample) 2022-04-28
CN111315412A (zh) 2020-06-19
CL2020000631A1 (es) 2020-09-11
RU2020113234A (ru) 2021-10-13
KR20200052331A (ko) 2020-05-14
BR112020004903A2 (pt) 2020-09-15

Similar Documents

Publication Publication Date Title
US20180333401A1 (en) Methods of treating liver disease
JP7860961B2 (ja) 原発性胆汁性胆管炎の治療のための組成物及び方法
US12310935B2 (en) Methods of treatment of cholestatic diseases
US11331292B2 (en) Methods of treatment of cholestatic diseases
JP2022516509A (ja) 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
US20240075030A1 (en) Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders
US20230235043A1 (en) Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
CN117677385A (zh) 用于治疗肝病的培马贝特和/或托格列净
US20130210861A1 (en) Methods and compositions for managing cardiovascular disease associated with chronic kidney disease
EP4247382A1 (en) Methods of treating systemic lupus erythematosus using btk inhibitors
CN110099686B (zh) 非酒精性脂肪性肝病的治疗
TW202313028A (zh) 使用s-羥氯喹的抗磷脂質症候群之治療
AU2024390210A1 (en) Therapies for the treatment of inflammatory bowel disease
EA050849B1 (ru) Композиции и способы лечения первичного билиарного холангита
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
HK40012462A (en) Treatment of nonalcoholic fatty liver disease
BR112020019172A2 (pt) tratamento e profilaxia de amiloidose

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230119

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230324